ArticleLasers in medical science2025
Efficacy of subliminal laser in chronic central serous chorioretinopathy: A 2.5-Year retrospective study.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To evaluate the efficacy and safety of subliminal laser therapy (SLT) in patients with chronic central serous chorioretinopathy (CSCR). Methods A 2.5-year retrospective analysis (October 2022-March 2025) was conducted on 27 eyes of 25 patients diagnosed with chronic CSCR. Power parameters were individually titrated for each eye. SLT parameters included a 577 nm yellow laser with a 5% duty cycle, pulse duration of 200 ms, and spot size of 160-200 μm. Patients were assessed using multimodal imaging: optical coherence tomography (OCT), OCT angiography, enhanced depth imaging OCT, fluorescein angiography, fundus autofluorescence, and color fundus photography. Results The mean duration of CSCR before SLT was 15.6 ± 11.2 months. 6-8 weeks after first laser application, central retinal thickness decreased from 369 ± 65 to 292 ± 51 μm (p = 0.0015). Visual acuity improved from 0.55 ± 0.16 to 0.67 ± 0.12 (p = 0.11). In 10 eyes (37%), a single SLT session was sufficient, 17 eyes (63%) required two sessions, and 2 eyes (7%) received three sessions. Additionally, 8 eyes (30%) required additional conventional focal laser treatment. Complete subretinal fluid resolution after SLT in the fovea occurred in 63% (17/27 eyes). No complications after SLT were observed. Conclusion SLT appears to be a safe, non-damaging, and effective treatment option for CSCR, particularly in settings where photodynamic therapy (PDT) is unavailable. Further prospective studies are needed to refine treatment protocols and assess long-term outcomes.
Indexed as
Identifiers
40974446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.